H U R I N E ALPHA-FETOPROTEIN - DEMONSTRATION AND DYNAMICS OF FOUR MOLECULAR FORMS IN CONCANAVALIN A CROSSED AFFINO-IMMUNOELECTROPHORESIS

1981 ◽  
pp. 327-338
Author(s):  
J. Hau ◽  
P. Svendsen ◽  
B. Teisner ◽  
G. Thomsen Pedersen
Keyword(s):  
Concanavalin A ◽  
Alpha Fetoprotein ◽  
Molecular Forms

Affinity chromatography used in distinguishing alpha-fetoprotein in serum from patients with tumors of hepatic parenchyma and of germ cells.

1984 ◽  
Vol 30 (7) ◽  
pp. 1257-1258 ◽  
Author(s):  
P K Buamah ◽  
C Cornell ◽  
A W Skillen
Keyword(s):  
Germ Cell ◽  
Affinity Chromatography ◽  
Germ Cells ◽  
Concanavalin A ◽  
Primary Liver Cancer ◽  
Germ Cell Tumors ◽  
Alpha Fetoprotein ◽  
Hepatic Parenchyma ◽  
Liver Cancers ◽  
Serum Alpha Fetoprotein

Abstract We used affinity chromatography on concanavalin A Sepharose to study the serum alpha-fetoprotein of 10 patients with histologically proven germ-cell tumors and 12 patients with primary liver cancer. Less than 50% of the fetoprotein from germ-cell tumors bound to concanavalin A, as compared with more than 80% of the alpha-fetoprotein from primary liver cancers.

Reactivity of amniotic fluid alpha-fetoprotein with concanavalin A in relation to gestational age: clinical implications.

1980 ◽  
Vol 26 (12) ◽  
pp. 1656-1659 ◽  
Author(s):  
K Toftager-Larsen ◽  
E Kjaersgaard ◽  
J C Jacobsen ◽  
B Nørgaard-Pedersen
Keyword(s):  
Amniotic Fluid ◽  
Clinical Significance ◽  
Concanavalin A ◽  
Gestational Age ◽  
Normal Values ◽  
Alpha Fetoprotein ◽  
Clinical Implications ◽  
Fetal Malformation ◽  
Average Decrease ◽  
Normal Outcome

Abstract We used concanavalin A crossed-line affinity immunoelectrophoresis to determine the percentage of concanavalin A nonreactive alpha-fetoprotein in amniotic fluid samples from pregnancies with normal and abnormal fetuses. In 167 samples from pregnancies with a normal outcome and normal values for total alpha-fetoprotein concentration in amniotic fluid the percentage decreased from a median value of 27.4% in the 13th week to 8.5% in the 21st week of gestation, and a statistically significant (p < 0.001) average decrease of 1.7% per week was found from the 14th to the 19th week. A similar average decrease (2.2%) was found in 22 pregnancies from which two or more samples were obtained. The clinical significance of this decrease is discussed. Of 108 samples from patients with above-normal values for total alpha-fetoprotein and a normal outcome, seven had a total alpha-fetoprotein above recommended cut-off values, and only one of these had a low percentage of concanavalin A nonreactive alpha-fetoprotein. In contrast, for all 27 samples from pregnancies with a severe fetal malformation this percentage was low, even in one case where the total alpha-fetoprotein concentration was below the recommended cut-off value.

Concanavalin A binding of alpha-fetoprotein in amniotic fluid as an aid in the diagnosis of neural tube defects.

1981 ◽  
Vol 27 (10) ◽  
pp. 1658-1660 ◽  
Author(s):  
P K Buamah ◽  
P Taylor ◽  
A M Ward
Keyword(s):  
Spina Bifida ◽  
Amniotic Fluid ◽  
Neural Tube ◽  
Neural Tube Defects ◽  
Concanavalin A ◽  
Gestational Age ◽  
Alpha Fetoprotein ◽  
Normal Outcome ◽  
Fetal Malformations ◽  
Open Spina Bifida

Abstract Concanavalin A nonreactive alpha-fetoprotein was determined in samples of amniotic fluid from 16 abnormal pregnancies complicated by anencephaly (7), open spina bifida (6), intra-uterine death (1), anencephaly with exomphalos (1), or open spina bifida with exomphalos (1), and in amniotic fluid from 50 normal pregnancies with gestational age between 13 and 24 weeks. In all 16 cases with fetal malformations, the proportion of nonreactive alpha-fetoprotein was significantly decreased (median 5.3%) as compared with amniotic fluid from pregnancies with a normal outcome (median 39.7%). The results confirm that this measurement is useful in the diagnosis of neural tube defects, especially when the concentration of alpha-fetoprotein in amniotic fluid is normal or only slightly above normal and gestational age is uncertain.

scholarly journals Diagnosis of hepatocellular carcinoma by concanavalin a affinity electrophoresis of serum alpha-fetoprotein

Cancer ◽  
1995 ◽  
Vol 76 (7) ◽  
pp. 1139-1144 ◽  
Author(s):  
Satoshi Saitoh ◽  
Kenji Ikeda ◽  
Isao Koida ◽  
Yoshiyuki Suzuki ◽  
Masahiro Kobayashi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Concanavalin A ◽  
Alpha Fetoprotein ◽  
Affinity Electrophoresis ◽  
Serum Alpha Fetoprotein

Interactions of Alpha-fetoprotein and Other Proteins with Concanavalin A

1978 ◽  
Vol 8 ◽  
pp. 319-322 ◽  
Author(s):  
C. DAMBUYANT ◽  
P. SIZARET ◽  
N. MARTEL ◽  
M. BORDES ◽  
C. BOURGEAUX
Keyword(s):  
Concanavalin A ◽  
Alpha Fetoprotein

Affinity chromatographic separation of alpha-fetoprotein variants: development of a mini-column procedure, and application to cancer patients.

1986 ◽  
Vol 32 (12) ◽  
pp. 2143-2146 ◽  
Author(s):  
D W Chan ◽  
Y C Miao
Keyword(s):  
Hepatocellular Carcinoma ◽  
Concanavalin A ◽  
Binding Capacity ◽  
Alpha Fetoprotein ◽  
Total Serum ◽  
Serial Determination ◽  
Analytical Recovery ◽  
Testicular Carcinoma ◽  
Serum Alpha Fetoprotein ◽  
Chromatographic Procedure

Abstract This is an affinity chromatographic procedure for separating variants of alpha-fetoprotein in 0.1 mL of serum on a disposable mini-column containing 0.9 mL of concanavalin A-Sepharose, at pH 6.4 and with a flow rate of 5 mL/h. The binding capacity of the column is 52 micrograms. Analytical recovery was 90%. Between-run CVs varied from 2.0% for samples with a high percentage of concanavalin A nonreactive fraction to 13% for samples with a low percentage. The mean proportion of nonreactive alpha-fetoprotein was 13.4% for patients with hepatocellular carcinoma, 62.2% for testicular carcinoma, and 8.9% for nonmalignant liver diseases. This suggests that the alpha-fetoprotein variants could be used to distinguish hepatocellular carcinoma from other carcinomas. Serial determination of the concanavalin A nonreactive fraction in such patients showed a relatively constant percentage. This indicates that monitoring variants in patients with hepatocellular carcinoma throughout their clinical course may not provide useful information additional to that provided by the values for total serum alpha-fetoprotein.

Sign in / Sign up

Export Citation Format

Share Document